血清microRNA用于子宫内膜异位症的无创诊断
本研究前瞻性纳入100例有妇科手术指征的女性,术前采集血清,用qRT-PCR检测6种microRNA,以腹腔镜所见为金标准,用随机森林算法构建诊断模型,并在48例独立样本中验证。结果显示联合模型在验证集中AUC达0.94,可区分子宫内膜异位症与其他妇科疾病。
要点
- 血清microRNA联合模型在独立验证集中诊断子宫内膜异位症的AUC为0.94。
- 单个microRNA的AUC范围为0.68至0.92,联合模型表现更优。
- 该模型可区分I/II期和III/IV期与对照,但I/II期与III/IV期之间无显著差异。
核心结论
- 血清microRNA生物标志物可可靠区分子宫内膜异位症与其他妇科病理,在两项独立研究中AUC均大于0.9。
研究设计与样本
- 前瞻性研究,在学术医疗中心纳入100例有妇科手术指征的女性,术前采集血清,以腹腔镜所见确定子宫内膜异位症存在与否。
- 使用qRT-PCR盲法检测6种血清microRNA:miR-125b-5p、miR-150-5p、miR-342-3p、miR-451a、miR-3613-5p和let-7b。
- 采用随机森林分类器构建基于microRNA表达值的算法,并在48例独立受试者(24例子宫内膜异位症和24例对照)中验证诊断性能。
主要发现
- 子宫内膜异位症组血清miR-125b-5p、miR-150-5p、miR-342-3p和miR-451a表达水平显著升高,miR-3613-5p和let-7b表达水平显著降低。
- 单个microRNA的受试者工作特征曲线下面积(AUC)范围为0.68至0.92。
- 联合microRNA的分类器在独立验证集中的AUC为0.94。
- 所有microRNA均可区分I/II期与对照以及III/IV期与对照,但I/II期与III/IV期之间的差异不显著。
- 亚组分析显示月经周期阶段或激素药物使用对算法中所用microRNA的表达水平均无显著影响。
临床怎么用
- 血清microRNA联合模型有潜力作为非侵入性工具检测子宫内膜异位症,可能缩短诊断时间并减少手术风险。
- 该检测可在临床环境中用于有妇科症状女性的早期识别,从而尽早治疗。
局限性
- 本研究为单中心前瞻性研究,验证集样本量较小(48例)。
- 对照组虽包含多种妇科病理,但以子宫肌瘤最常见(n=39),其他病理的代表性有限。
- 研究未报告模型在更广泛人群或不同疾病阶段中的外部验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endometriosis, a chronic disease that afflicts millions of women worldwide, has traditionally been diagnosed by laparoscopic surgery. This diagnostic barrier delays identification and treatment by years, resulting in prolonged pain and disease progression. Development of a noninvasive diagnostic test could significantly improve timely disease detection. We tested the feasibility of serum microRNAs as diagnostic biomarkers of endometriosis in women with gynecologic disease symptoms. OBJECTIVE: The objective of the study was to validate the use of a microRNA panel as a noninvasive diagnostic method for detecting endometriosis. STUDY DESIGN: This was a prospective study evaluating subjects with a clinical indication for gynecological surgery in an academic medical center. Serum samples were collected prior to surgery from 100 subjects. Women were selected based on the presence of symptoms, and laparoscopy was performed to determine the presence or absence of endometriosis. The control group was categorized based on absence of visual disease at the time of surgery. Circulating miRNAs, miR-125b-5p, miR-150-5p, miR-342-3p, miR-451a, miR-3613-5p, and let-7b, were measured in serum by quantitative real-time polymerase chain reaction in a blinded fashion without knowledge of disease status. Receiver-operating characteristic analysis was performed on individual microRNAs as well as combinations of microRNAs. An algorithm combining the expression values of these microRNAs, built using machine learning with a random forest classifier, was generated to predict the presence or absence of endometriosis on operative findings. This algorithm was then tested in an independent data set of 48 previously identified subjects not included in the training set (24 endometriosis and 24 controls) to validate its diagnostic performance. RESULTS: The mean age of women in the study population was 34.1 and 36.9 years for the endometriosis and control groups, respectively. Control group subjects displayed varying pathologies, with leiomyoma occurring the most often (n = 39). Subjects with endometriosis had significantly higher expression levels of 4 serum microRNAs: miR-125b-5p, miR-150-5p, miR-342-3p, and miR-451a. Two serum microRNAs showed significantly lower levels in the endometriosis group: miR-3613-5p and let-7b. Individual microRNAs had receiver-operating characteristic areas under the curve ranging from 0.68 to 0.92. A classifier combining these microRNAs yielded an area under the curve of 0.94 when validated in the independent set of subjects not included in the training set. Analysis of the expression levels of each microRNA based on revised American Society of Reproductive Medicine staging revealed that all microRNAs could distinguish stage I/II from control and stage III/IV from control but that the difference between stage I/II and stage III/IV was not significant. Subgroup analysis revealed that neither phase of the menstrual cycle or use of hormonal medication had a significant impact on the expression levels in the microRNAs used in our algorithm. CONCLUSION: This is the first report showing that microRNA biomarkers can reliably differentiate between endometriosis and other gynecological pathologies with an area under the curve >0.9 across 2 independent studies. We validated the performance of an algorithm based on previously identified microRNA biomarkers, demonstrating their potential to detect endometriosis in a clinical setting, allowing earlier identification and treatment. The ability to diagnose endometriosis noninvasively could reduce the time to diagnosis, surgical risk, years of discomfort, disease progression, associated comorbidities, and health care costs.
引用
- Moustafa S, Burn M, Mamillapalli R, et al. Accurate diagnosis of endometriosis using serum microRNAs. Am J Obstet Gynecol. 2020. PMID: 32165186. doi:10.1016/j.ajog.2020.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。